Healthcare
VVT Med Expands European Commercial Footprint Through Exclusive Distribution Agreement in Greece
VVT Med Inc. (TSXV: VVTM) ("VVTMed" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent solutions for venous disease, today announced the signing of an exclusive distribution agreement dated June 25, 2026 for the commercialization of the Company's VVT's ScleroSafe® platform in Greece (the "Distribution Agreement") with General Chemical Products S.A. ("GCP"), an established Greek medical technology company with more than four decades of experience supporting hospitals
About this update from Vvt Med Inc.
VANCOUVER, BC, June 26, 2026 /CNW/ - VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent solutions for venous disease, today announced the signing of an exclusive distribution agreement dated June 25, 2026 for the commercialization of the Company's VVT's ScleroSafe® platform in Greece (the "Distribution Agreement") with General Chemical Products S.A. ("GCP"), an established Greek medical technology company with more than four decades of experience supporting hospitals and healthcare professionals through the commercialization of innovative medical devices and clinical solutions. The Distribution Agreement grants GCP exclusive distribution rights for VVT's ScleroSafe® platform in Greece for an initial five-year term. The Distribution Agreement may be terminated prior to the expiry of the initial term under customary circumstances, including for an uncured material breach, insolvency or bankruptcy of either party, failure by the distributor to satisfy certain minimum sales requirements, or where otherwise permitted under the agreement. The Distribution Agreement contains minimum purchase commitments with an aggregate contractual value of approximately €712,800 (approximately CAD$1.14 million based on current exchange rates) over the initial five-year term, exclusive of any purchases beyond the contractual minimum commitments. The Distribution Agreement further expands VVT Med's European distribution network and establishes a commercial presence for ScleroSafe® in the Greek market. Erez Tetro, Chief Executive Officer of VVT Med, commented: "We are pleased to enter the Greek market through our partnership with GCP. GCP's long-standing reputation and commercial infrastructure make them an excellent partner for the introduction of ScleroSafe® in Greece. This agreement expands our European distribution network and supports our strategy of increasing international access to ScleroSafe®. We look forward to working with GCP to introduce the technology to physicians and patients throughout Greece." GCP is an established Greek medical technology company with more than 40 years of market presence. The company partners with international medical technology manufacturers and provides sales, logistics, technical support and clinical services to healthcare providers across Greece. About VVT M...